Athersys (NASDAQ:ATHX) has been assigned a $8.00 price objective by equities research analysts at Maxim Group in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target indicates a potential upside of 422.88% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of Athersys from a “sell” rating to a “strong sell” rating in a research note on Friday, November 16th. Zacks Investment Research downgraded shares of Athersys from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, ValuEngine downgraded shares of Athersys from a “buy” rating to a “hold” rating in a report on Thursday, January 10th.

Shares of NASDAQ:ATHX traded up $0.14 during trading on Wednesday, reaching $1.53. 73,476 shares of the company traded hands, compared to its average volume of 423,888. The firm has a market capitalization of $202.70 million, a P/E ratio of -5.30 and a beta of 0.03. Athersys has a 1-year low of $1.29 and a 1-year high of $3.09.

Athersys (NASDAQ:ATHX) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.32 million during the quarter, compared to analyst estimates of $1.80 million. Athersys had a negative net margin of 108.83% and a negative return on equity of 58.74%. Sell-side analysts expect that Athersys will post -0.19 earnings per share for the current year.

In other news, insider William Lehmann, Jr. sold 15,000 shares of the firm’s stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $1.73, for a total transaction of $25,950.00. Following the transaction, the insider now owns 493,062 shares in the company, valued at approximately $852,997.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.60% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in shares of Athersys during the 3rd quarter valued at $59,000. Alps Advisors Inc. raised its holdings in Athersys by 22.5% in the 3rd quarter. Alps Advisors Inc. now owns 245,240 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 45,024 shares during the period. Renaissance Technologies LLC raised its holdings in Athersys by 21.3% in the 2nd quarter. Renaissance Technologies LLC now owns 439,900 shares of the biopharmaceutical company’s stock worth $867,000 after acquiring an additional 77,100 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Athersys by 50.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 250,900 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 84,600 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Athersys by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 5,707,784 shares of the biopharmaceutical company’s stock worth $11,986,000 after acquiring an additional 134,541 shares during the period. Institutional investors and hedge funds own 19.55% of the company’s stock.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also: Investing in Blue-Chip Stocks

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.